Express News | Alnylam Pharmaceuticals Inc : JP Morgan Cuts Target Price to $166 From $170
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's (NYSE:ALNY) short percent of float has fallen 9.57% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 2.55% of all reg
Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsApr 18, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the lead
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran when added
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Alnylam Pharmaceuticals (ALNY) was
Sector Update: Health Care
Health care stocks were flat to higher premarket Monday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was recently up 0.2%. Alnylam Pharmaceutic
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Alnylam Pharmaceuticals (ALNY) said Sunday that a phase 2 study evaluating the investigational drug zilebesiran in treating hypertension has met its primary endpoint. Zilebesiran reached the study's p
Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3A Single D
Alnylam Presents Positive Results From the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients With Inadequately Controlled Hypertension
Apr. 7, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan).
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 1.97% on an annualized basis producing an average annual return of 15.0%. Currently, Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-sales (or "P/S") ratio of 10.6x Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) may be sending bullish signals at the moment, given that almost half of all the Biotechs companies in the Un
Those Who Invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) Five Years Ago Are up 63%
BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Maintains $234 Price Target
BMO Capital analyst Kostas Biliouris maintains Alnylam Pharmaceuticals with a Outperform and maintains $234 price target.
Alnylam to Webcast Investor Event to Discuss Results From KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionMar 20, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar.
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 1.77% on an annualized basis producing an average annual return of 14.93%. Currently, Alnylam Pharmaceutical
Alnylam Launches Hereditary ATTR (HATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseMar 13, 2024– Family Health History Road Trip Program Aims
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock
Over the past year, many Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insiders sold a significant stake in the company which may have piqued investors' interest. When analyzing insider transactions,
No Data